Parabilis Medicines, Inc.
PBLS
$28.80
$2.449.26%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -45.32M | -38.33M | |||
| Total Depreciation and Amortization | 606.00K | 654.00K | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 3.04M | 2.65M | |||
| Change in Net Operating Assets | -7.53M | 871.00K | |||
| Cash from Operations | -49.20M | -34.15M | |||
| Capital Expenditure | -369.00K | -74.00K | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | 6.76M | |||
| Cash from Investing | -369.00K | 6.69M | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -3.90M | -140.00K | |||
| Issuance of Common Stock | 187.00K | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | 305.25M | 67.49M | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | 49.37M | -62.00K | |||
| Cash from Financing | 350.90M | 67.29M | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 301.33M | 39.82M | |||